Shailender Bhatia, MD
Medical Oncology · Seattle, WANPI 1225041791
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (49.7%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by EMD Serono, Inc. at 45.0% of the total. Among medical oncology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 43 payments — averaging $2489.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$48K
- Sanofi$17K
- Regeneron$13K
- Merck$9K
- E.r. Squibb & Sons, L.L.C.$8K
- Incyte Corporation$5K
- plus $7K from 4 others
Across 916 payments — averaging $8067.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- EMD Serono, Inc.$2.2M
- E.r. Squibb & Sons, L.L.C.$1.4M
- Incyte Corporation$1.2M
- Regeneron$1.2M
- Merck$510K
- EMD Serono Research & Development Institute, Inc.$367K
- plus $499K from 3 others
What the payments were for
- Consulting fees$33,09731%
- Speaking & faculty fees$19,45418%
- Travel & lodging$53,20150%
- Food & beverage$1,3031%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 7 | $48,160 |
| Sanofi | 7 | $17,380 |
| Regeneron | 4 | $13,208 |
| Merck | 11 | $8,975 |
| E.r. Squibb & Sons, L.L.C. | 4 | $7,710 |
| Incyte Corporation | 1 | $4,999 |
| Regeneron Healthcare Solutions, Inc. | 2 | $3,400 |
| Immunocore Limited | 1 | $2,400 |
| Trisalus Life Sciences, Inc. | 3 | $432 |
| Clinigen, Inc. | 3 | $392 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$20,730
- OPDIVO$3,900
- KIMMTRAK$2,400
- TRINAV INFUSION SYSTEM$402
- Proleukin$302
How this compares
$107,055 in reported general payments places this provider in the 90th percentile of 162 medical oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Seattle
- Bart ScottSeattle$1.3M
- Petros GrivasSeattle$628K
- Vijayakrishna GadiSeattle$573K
- Evan YuSeattle$296K
- Siddhartha DevarakondaSeattle$215K
- David MaloneySeattle$150K
- Gary LymanSeattle$130K
- Rafic FarahSeattle$114K
- Laura ChowSeattle$114K
- Diane TsengSeattle$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.